# A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07174583/  
OnCo record `nct07174583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Durvalumab, Carboplatin in small-cell lung cancer, run by IDEAYA Biosciences, now recruiting.

## Summary

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07174583 by IDEAYA Biosciences, with 262 participants planned, started 2025-10-14 and due to reach its primary completion in 2029-07. Interventions recorded: IDE849, durvalumab, IDE161, Carboplatin. Conditions listed: Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07174583
- Phase: 1/2
- Setting: A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer
- Sponsor: IDEAYA Biosciences
- Enrolled: 262

## Sources

- ClinicalTrials.gov NCT07174583: https://clinicaltrials.gov/study/NCT07174583

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07174583.json